Are plasma insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer?

International Journal of Biological Markers

Volumn 19, Issue 2, 2004, Pages 164-167

  Lopez, J B ^a   Sahabudin, R M ^b   Chin, L P ^a  

^a INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

^b HOSPITAL KUALA LUMPUR   (Malaysia)

Author keywords

Benign prostatic hyperplasia; IGF 1; IGFBP 3; Prostate cancer; PSA

Indexed keywords

BIOCHEMICAL MARKER; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED MEDICINE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; RANK SUM TEST; STATISTICAL ANALYSIS;

EID: 4243202854     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080401900213     Document Type: Article

References (17)

1. Nash AF, Melezinek I. The role of prostate specific antigen measurement in the detection and management of prostate cancer. Endocrine-Related Cancer 2000; 7: 35-51.
2. Khosravi J, Diamandi A, Mistry J, Scorilas A. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. J Clin Endocrinol Metab 2001; 86: 694-9.
3. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor and prostate cancer risk: a prospective study. Science 1998; 279: 563-6.
4. Wolk A, Christos SM, Andersson S-O, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-5.
5. Stattin P, Bylund A, Rinaldi S, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000; 92: 1910-7.
6. Chokkalingam AP, Gao YT, Deng J, et al. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate 2002; 52: 98-105.
7. Miyata Y, Sakai H, Hayashi T, Kanetake H. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate 2003; 54: 125-32.
8. Kanety H, Madjar Y, Dagan Y, et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993; 77: 229-33.
9. Baffa R, Reiss K, El-Gabry EA, et al. Low serum insulin-like growth factor I (IGF-I): a significant association with prostate cancer. Tech Urol 2000; 6: 236-9.
10. Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab 1996; 81: 411-20.
11. Finne P, Auvinen A, Koistinen H, et al. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 2000; 85: 2744-7.
12. Cutting CW, Hunt C, Nisbet JA, Bland JM, Dalgleish AG, Kirby RS. Serum insulin-like growth factor-I is not a useful marker of prostate cancer. BJU Int 1999; 83: 996-9.
13. Ismail AH, Pollak M, Behlouli H, Tanguay S, Begin LR, Aprikian AG. Insulin-like growth factor and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy. J Urol 2002; 168: 2426-30.
14. Koliakos G, Chatzivasiliou D, Dimopoulos T, et al. The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer. Dis Markers 2000; 16: 143-6.
15. Kurek R, Tunn UW, Eckart O, Aumuller G, Wong J, Renneberg H. The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer. BJU Int 2000; 85: 125-9.
16. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993; 76: 1031-5.
17. Yu H, Nicar MR, Shi R, et al. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology 2001; 57: 471-5.